51
|
Xie SW, Li HL, Du J, Xia JG, Guo YF, Xin M, Li FH. Contrast-enhanced ultrasonography with contrast-tuned imaging technology for the detection of prostate cancer: comparison with conventional ultrasonography. BJU Int 2011; 109:1620-6. [PMID: 21939490 DOI: 10.1111/j.1464-410x.2011.10577.x] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
UNLABELLED Study Type - Diagnostic (exploratory cohort) Level of Evidence 2b What's known on the subject? and What does the study add? The present study was to perform contrast-tuned imaging (CnTI) technology to detect prostate cancer and compare the use of CnTI technology for the detection of prostate cancer with conventional ultrasonography. The preliminary data from our study suggested that targeted biopsy of the prostate with CnTI technology could improve the cancer detection and detect higher grade prostate cancers. OBJECTIVES To perform contrast-enhanced ultrasonography (CEUS) using contrast-tuned imaging (CnTI) technology to detect prostate cancer. To evaluate the detection of prostate cancer with CnTI compared with conventional grey-scale and power Doppler ultrasonography. PATIENTS AND METHODS In all, 150 patients referred for prostate biopsy were evaluated using transrectal grey-scale, power Doppler and CnTI ultrasonography. Biopsy was performed at 10 sites in each patient. If an abnormality was found at any of these three ultrasonography examinations, a biopsy specimen was targeted towards from the corresponding site. The performances of the three ultrasonography techniques for prostate cancer detection were compared. RESULTS Prostate cancer was detected at 383 sites from 73 patients. The combination of these three examinations detected more patients with prostate cancer than grey-scale (P= 0.002), power Doppler (P= 0.001) or baseline imaging (the combination of grey-scale and power Doppler; P= 0.031) alone. By biopsy site, CnTI had higher sensitivity and accuracy (73.1% and 83.7%) than grey-scale (50.9%; P < 0.001 and 78.8%; P < 0.001) or power Doppler (48.3%; P < 0.001 and 77.7%; P < 0.001), while the specificity was similar for grey-scale (88.4%), power Doppler (87.8%) and CnTI (87.3%; P > 0.05 in each case). CnTI had higher sensitivity (73.1% vs 62.9%; P < 0.001), specificity (87.3% vs 82.1%; P < 0.001) and accuracy (83.7% vs 77.2%; P < 0.001) than baseline imaging. The mean Gleason score of CnTI-positive cases was significantly higher than CnTI-negative cases (7.1 vs 6.3; P= 0.002). CONCLUSIONS CEUS using CnTI technology enables a visualization of the microvasculature associated with prostate cancer. CnTI technology could be used to guide biopsy and improve the detection rate of prostate cancer. CnTI technology was able to detect higher grade prostate cancers.
Collapse
Affiliation(s)
- Shao Wei Xie
- Department of Ultrasound, Shanghai Jiao Tong University, Shanghai, China
| | | | | | | | | | | | | |
Collapse
|
52
|
Nepple KG, Rosevear HM, Stolpen AH, Brown JA, Williams RD. Concordance of preoperative prostate endorectal MRI with subsequent prostatectomy specimen in high-risk prostate cancer patients. Urol Oncol 2011; 31:601-6. [PMID: 21665495 DOI: 10.1016/j.urolonc.2011.05.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2011] [Revised: 04/25/2011] [Accepted: 05/01/2011] [Indexed: 01/08/2023]
Abstract
OBJECTIVE Endorectal MRI (ER-MRI) may identify areas suspicious for prostate cancer. We evaluated the accuracy of ER-MRI compared with subsequent pathology specimen from prostatectomy. MATERIALS AND METHODS We reviewed 309 open radical retropubic prostatectomy cases (RRP) from 2003 to 2008 to identify 94 men with a preoperative ER-MRI, which was obtained in patients with high-risk factors suspicious for local extension (Gleason grade ≥ 4+3, PSA ≥ 10 ng/ml, abnormal rectal exam, or extensive biopsy core involvement). Findings of extracapsular extension (ECE), seminal vesicle invasion (SVI), and lymphadenopathy (LAD) on ER-MRI were compared with subsequent findings on pathology specimens. RESULTS Ninety-four men underwent preoperative ER-MRI. No tumor was seen on ER-MRI in 9 men (10%). Of 94 ER-MRIs, 4% showed SVI, and 12% had ECE. At prostatectomy, lymph nodes were pathologically positive in 10 men, none of which were enlarged on ER-MRI. RRP was aborted in 3 of these 10 patients due to positive nodes confirmed on frozen section. Comparing ER-MRI results to subsequent prostatectomy specimen the results for accuracy, positive predictive value, negative predictive value, sensitivity, specificity were 70%, 27%, 76%, 14%, 88% for ECE and 93%, 75%, 94%, 38%, 99% for SVI. The accuracy of ECE prediction was 86% in abnormal rectal exam vs. 66% in normal exam (P < 0.05). CONCLUSIONS Endorectal MRI in the evaluation of high-risk prostate cancer was moderately accurate for SV involvement but inaccurate for ECE and insensitive for metastatic lymph node involvement. The predictive accuracy of ER-MRI improved in patients with an abnormal rectal exam.
Collapse
Affiliation(s)
- Kenneth G Nepple
- Department of Urology, University of Iowa, Iowa City, IA 52242, USA
| | | | | | | | | |
Collapse
|
53
|
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011; 60:291-303. [PMID: 21601982 DOI: 10.1016/j.eururo.2011.05.006] [Citation(s) in RCA: 243] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2011] [Accepted: 05/02/2011] [Indexed: 01/19/2023]
Abstract
CONTEXT The notion of insignificant prostate cancer (Ins-PCa) has progressively emerged in the past two decades. The clinical relevance of such a definition was based on the fact that low-grade, small-volume, and organ-confined prostate cancer (PCa) may be indolent and unlikely to progress to biologic significance in the absence of treatment. OBJECTIVE To review the definition of Ins-PCa, its incidence, and the clinical impact of Ins-PCa on the contemporary management of PCa. EVIDENCE ACQUISITION A review of the literature was performed using the Medline, Scopus, and Web of Science databases with no restriction on language up to September 2010. The literature search used the following terms: insignificant, indolent, minute, microfocal, minimal, low volume, low risk, and prostate cancer. EVIDENCE SYNTHESIS The most commonly used criteria to define Ins-PCa are based on the pathologic assessment of the radical prostatectomy specimen: (1) Gleason score ≤ 6 without Gleason pattern 4 or 5, (2) organ-confined disease, and (3) tumour volume<0.5 cm(3). Several preoperative criteria and prognostication tools for predicting Ins-PCa have been suggested. Nomograms are best placed to estimate the risk of progression on an individualised basis, but a substantial proportion of men with a high probability of harbouring Ins-PCa are at risk for pathologic understaging and/or undergrading. Thus, there is an ongoing need for identifying novel and more accurate predictors of Ins-PCa to improve the distinction between insignificant versus significant disease and thus to promote the adequate management of PCa patients at low risk for progression. CONCLUSIONS The exciting challenge of obtaining the pretreatment diagnostic tools that can really distinguish insignificant from significant PCa should be one of the main objectives of urologists in the following years to decrease the risk of overtreatment of Ins-PCa.
Collapse
|
54
|
Roethke M, Anastasiadis AG, Lichy M, Werner M, Wagner P, Kruck S, Claussen CD, Stenzl A, Schlemmer HP, Schilling D. MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy. World J Urol 2011; 30:213-8. [PMID: 21512807 DOI: 10.1007/s00345-011-0675-2] [Citation(s) in RCA: 105] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2011] [Accepted: 03/28/2011] [Indexed: 10/18/2022] Open
Abstract
PURPOSE To investigate the positive biopsy rate of MRI-guided biopsy (MR-GB) in a routine clinical setting, identify factors predictive for positive biopsy findings and to report about the clinical significance of the diagnosed tumors. METHODS Patients with at least one negative trans-rectal-ultrasound-guided biopsy (TRUS-GB), persistently elevated or rising serum prostate specific antigen (PSA) and at least one lesion suspicious for PCa on diagnostic 1.5 Tesla endorectal coil MRI (eMR) were included. Biopsies were carried out using a 1.5 Tesla MRI and an 18 G biopsy gun. Clinical information and biopsy results were collected; logistic regression analysis was carried out. Definite pathology reports of patients with diagnosis of PCa and subsequent radical prostatectomy (RP) were analyzed for criteria of clinical significance. RESULTS One hundred patients were included, mean number of previous biopsies was 2 (range 1-9), mean PSA at time of biopsy was 11.7 ng/ml (1.0-65.0), and mean prostate volume was 46.7 ccm (range 13-183). In 52/100 (52.0%) patients, PCa was detected. Out of 52 patients, 27 patients with a positive biopsy underwent RP, 20 patients radiation therapy, and 5 patients active surveillance. In total, 80.8% of the patients revealed a clinically significant PCa. In univariate regression analysis, only serum PSA levels were predictive for a positive biopsy result. Number of preceding negative biopsies was not associated with the likelihood of a positive biopsy result. CONCLUSIONS MR-GB shows a high detection rate of clinically significant PCa in patients with previous negative TRUS-GB and persisting suspicion for PCa.
Collapse
Affiliation(s)
- M Roethke
- Department of Radiology, Comprehensive Cancer Center (CCC) Tübingen, Eberhard-Karls-Universität, Tübingen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
55
|
Klomp DWJ, Scheenen TWJ, Arteaga CS, van Asten J, Boer VO, Luijten PR. Detection of fully refocused polyamine spins in prostate cancer at 7 T. NMR IN BIOMEDICINE 2011; 24:299-306. [PMID: 20925128 DOI: 10.1002/nbm.1592] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2010] [Revised: 06/19/2010] [Accepted: 06/21/2010] [Indexed: 05/30/2023]
Abstract
(1)H MRSI is often used at 1.5 or 3 T to study prostate cancer, where the ratio of choline + creatine to citrate is taken as a marker for tumour presence. Recently, the level of polyamines (mainly spermine) has been shown to improve specificity even further. However, the in vivo detection of these polyamines (at 3.1 ppm) is hampered by signal cancellation as a result of J-coupling effects and signal overlap with choline (3.2 ppm) and creatine (3.0 ppm) resonances. At higher magnetic field strengths, the chemical shift dispersion will increase, which allows the use of very selective radiofrequency pulses to refocus J-coupled spins. In this work, we added selective refocusing pulses to a semi-LASER (localisation based on adiabatic selective refocusing) sequence at 7 T, and optimised the inter-pulse timings of the sequence for fully refocused detection of spermine spins, whilst maintaining optimised detection of choline, creatine and the strongly coupled spin system of citrate.
Collapse
Affiliation(s)
- D W J Klomp
- Department of Radiology, Radiotherapy and Nuclear Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
| | | | | | | | | | | |
Collapse
|
56
|
McLean MA, Barrett T, Gnanapragasam VJ, Priest AN, Joubert I, Lomas DJ, Neal DE, Griffiths JR, Sala E. Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla. Magn Reson Med 2011; 65:914-9. [PMID: 21413057 DOI: 10.1002/mrm.22703] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2010] [Revised: 09/29/2010] [Accepted: 10/03/2010] [Indexed: 11/10/2022]
Abstract
(1)H magnetic resonance spectroscopic imaging was performed on 16 men with suspected prostate cancer using an 8-channel external receive coil at 3 T. Choline and citrate (Cit) signals were measured in prostate lesions and normal-appearing peripheral zone as identified on T(2)-weighted images. Metabolites were quantified relative to unsuppressed water from a separately acquired magnetic resonance spectroscopic imaging dataset using LCModel. Validation experiments were also performed in a phantom containing physiological concentrations of choline, Cit, and creatine. In vitro, fair agreement between measured and true concentrations was observed, with the greatest discrepancy being a 35% underestimation of Cit. In vivo, one dataset was rejected for failure to meet the quality criterion of linewidth <15 Hz, and in 6 of 15 subjects, insufficient normal-appearing peripheral zone tissue was identified for study. Lesions were found to have higher choline and choline/Cit, and lower Cit, than normal-appearing peripheral zone. The smaller skew of data obtained using water normalization in comparison with metabolite ratios suggests potential usefulness in longitudinal tumor monitoring and in studies of treatment effects.
Collapse
Affiliation(s)
- Mary A McLean
- Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge, United Kingdom.
| | | | | | | | | | | | | | | | | |
Collapse
|
57
|
Roberts MJ, Schirra HJ, Lavin MF, Gardiner RA. Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean J Urol 2011; 52:79-89. [PMID: 21379423 PMCID: PMC3045724 DOI: 10.4111/kju.2011.52.2.79] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2010] [Accepted: 01/07/2011] [Indexed: 12/22/2022] Open
Abstract
Prostate cancer (PCa) is the most commonly diagnosed visceral cancer in men and is responsible for the second highest cancer-related male mortality rate in Western countries, with increasing rates being reported in Korea, Japan, and China. Considering the low sensitivity of prostate-specific antigen (PSA) testing, it is widely agreed that reliable, age-independent markers of the presence, nature, and progression of PCa are required to facilitate diagnosis and timely treatment. Metabolomics or metabonomics has recently emerged as a novel method of PCa detection owing to its ability to monitor changes in the metabolic signature, within biofluids or tissue, that reflect changes in phenotype and function. This review outlines the physiology of prostate tissue and prostatic fluid in health and in malignancy in relation to metabolomics as well as the principles underlying the methods of metabolomic quantification. Promising metabolites, metabolic profiles, and their correlation with the presence and stage of PCa are summarized. Application of metabolomics to biofluids and in vivo quantification as well as the direction of current research in supplementing and improving current methods of detection are discussed. The current debate in the urology literature on sarcosine as a potential biomarker for PCa is reviewed and discussed. Metabolomics promises to be a valuable tool in the early detection of PCa that may enable earlier treatment and improved clinical outcomes.
Collapse
Affiliation(s)
- Matthew J. Roberts
- Department of Urology, University of Queensland Centre for Clinical Research, Brisbane, Australia
| | - Horst J. Schirra
- The University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, Australia
| | - Martin F. Lavin
- Queensland Institute of Medical Research, Radiation Biology and Oncology, Brisbane, Australia
- Department of Surgery, University of Queensland Centre for Clinical Research, Brisbane, Australia
| | - Robert A. Gardiner
- Department of Surgery, University of Queensland Centre for Clinical Research, Brisbane, Australia
- Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia
| |
Collapse
|
58
|
Villeirs GM, De Meerleer GO, De Visschere PJ, Fonteyne VH, Verbaeys AC, Oosterlinck W. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients. Eur J Radiol 2011; 77:340-5. [DOI: 10.1016/j.ejrad.2009.08.007] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2009] [Revised: 08/04/2009] [Accepted: 08/06/2009] [Indexed: 10/20/2022]
|
59
|
Klijn S, De Visschere PJ, De Meerleer GO, Villeirs GM. Comparison of qualitative and quantitative approach to prostate MR spectroscopy in peripheral zone cancer detection. Eur J Radiol 2011; 81:411-6. [PMID: 21215541 DOI: 10.1016/j.ejrad.2010.12.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2010] [Accepted: 12/02/2010] [Indexed: 01/08/2023]
Abstract
OBJECTIVE To compare the diagnostic performance of a qualitative (pattern recognition) and a quantitative (numerical assessment) approach to magnetic resonance spectroscopy (MRS) in the diagnosis of peripheral zone prostate cancer. METHODS 185 patients (131 with histopathologically proven cancer, 54 normal/benign after at least 12 months follow-up) were prospectively evaluated with qualitative MRS using a 4-point scale between 3/2004 and 1/2008, and retrospectively reassessed using a prototype quantitative postprocessing software in April 2008. Based on pathology and follow-up data, diagnostic performance parameters were calculated. RESULTS The qualitative and quantitative approaches were concordant in 78.9% (146/185) of cases. The difference between the areas under the ROC curve (0.791 versus 0.772, respectively) was not statistically significant. The sensitivity, specificity and accuracy were 55.7%, 94.4% and 67.0% for the qualitative approach, and 55.0%, 83.3% and 63.2% for the quantitative approach. The sensitivity for high grade tumours (Gleason 4+3 or higher) was 85.2% (23/27) for both approaches. All cancers missed on either one approach separately (31/31) and 91% of cancers missed on both approaches together (23/27) were of lower grade (Gleason 3+4 or lower). CONCLUSIONS Qualitative and quantitative approaches to MRS yield similar diagnostic results. Discordances in tumour detection only occurred in lower grade cancers.
Collapse
Affiliation(s)
- Stijn Klijn
- Division of Genitourinary Radiology, Ghent University Hospital, De Pintelaan 185, 9000 Gent, Belgium
| | | | | | | |
Collapse
|
60
|
Ploussard G, Xylinas E, Durand X, Ouzaïd I, Allory Y, Bouanane M, Abbou CC, Salomon L, de la Taille A. Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme. BJU Int 2010; 108:513-7. [DOI: 10.1111/j.1464-410x.2010.09974.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
61
|
Lecornet E, Moore C, Ahmed HU, Emberton M. Focal therapy for prostate cancer: fact or fiction? Urol Oncol 2010; 28:550-6. [PMID: 20816615 DOI: 10.1016/j.urolonc.2010.08.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Prostate cancer is the commonest male cancer diagnosed in men in the UK, and the treatment of organ confined prostate cancer is a subject of much debate. Focal therapy for prostate cancer intends to treat the cancer within the prostate, whilst sparing the majority of the benign prostate tissue. In addition, the intention is to avoid treatment effects in the surrounding structures, the damage of which leads to the side effects commonly associated with radical whole gland therapies. This relies on accurate localization of the prostate cancer by biopsy and imaging followed by treatment using a modality capable of delivery to a focal area within the prostate. Focal therapy lies between the current extremes of radical whole gland treatment and active surveillance. There have been many articles reviewing the concept of focal therapy for organ confined prostate cancer, but with a paucity of data available for analysis. This is being addressed with an increase in the published data on focal therapy, using a number of different modalities. In this review, we address the question of whether the data currently published does in fact support the further development of the focal therapy approach, or whether it is a concept best relegated to the realms of fiction.
Collapse
Affiliation(s)
- Emilie Lecornet
- Division of Surgery and Interventional Sciences, University College of London, London, United Kingdom.
| | | | | | | |
Collapse
|
62
|
Komoroski RA, Holder JC, Pappas AA, Finkbeiner AE. 31P NMR of phospholipid metabolites in prostate cancer and benign prostatic hyperplasia. Magn Reson Med 2010; 65:911-3. [PMID: 20967792 DOI: 10.1002/mrm.22677] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2010] [Revised: 09/16/2010] [Accepted: 09/19/2010] [Indexed: 11/10/2022]
Abstract
(1)H MRSI in vivo is increasingly being used to diagnose prostate cancer noninvasively by measurement of the resonance from choline-containing phospholipid metabolites. Although (31) P NMR in vivo or in vitro is potentially an excellent method for probing the phospholipid metabolites prominent in prostate cancer, it has been little used recently. Here, we report an in vitro (31)P NMR comparison of prostate cancer and benign prostatic hyperplasia, focusing on the levels of the major phospholipid metabolites. Unlike phosphocholine and glycerophosphocholine, phosphoethanolamine and glycerophosphoethanolamine (and their ratio) were significantly different between cancer and benign prostatic hyperplasia. The high level of phosphoethanolamine+glycerophosphoethanolamine relative to phosphocholine+glycerophosphocholine suggests that the former may be significant contributors to the "total choline" resonance observed by (1)H MRSI in vivo.
Collapse
Affiliation(s)
- Richard A Komoroski
- Center for Imaging Research and Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio 45267-0583, USA.
| | | | | | | |
Collapse
|
63
|
Afaq A, Andreou A, Koh DM. Diffusion-weighted magnetic resonance imaging for tumour response assessment: why, when and how? Cancer Imaging 2010; 10 Spec no A:S179-88. [PMID: 20880779 PMCID: PMC2967137 DOI: 10.1102/1470-7330.2010.9032] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
Diffusion-weighted magnetic resonance imaging (DWI) is increasingly being used to assess tumour response to a variety of anticancer treatments. The technique is quick to perform without the need for administration of exogenous contrast medium, and enables the apparent diffusion coefficient (ADC) of tissues to be quantified. Studies have shown that ADC increases in response to a variety of treatments including chemotherapy, radiotherapy, minimally invasive therapies and novel therapeutics. In this article, we review the rationale of applying DWI for tumour assessment, the evidence for ADC measurements in relation to specific treatments and some of the practical considerations for using ADC to evaluate treatment response.
Collapse
Affiliation(s)
- A Afaq
- Royal Marsden Hospital, Downs Road, Sutton, UK
| | | | | |
Collapse
|
64
|
Tsivian M, Hruza M, Mouraviev V, Rassweiler J, Polascik TJ. Prostate biopsy in selecting candidates for hemiablative focal therapy. J Endourol 2010; 24:849-53. [PMID: 20370327 DOI: 10.1089/end.2009.0473] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Focal therapy (FT) for the management of clinically localized prostate cancer (PCa) is growing from a concept to reality because of increased interest of both patients and physicians. Selection protocols, however, are yet to be established. We discuss the role of prostate biopsy in candidate selection for FT and highlight the different strategies and technical aspects of the use of prostate biopsy in this setting. In our opinion, prostate biopsy plays a major role in the selection process and tailoring appropriate treatment strategy to the patient. FT necessitates dedicated biopsy schemes that would reliably predict the extent, nature, and location of PCa in selected patients. Currently, there is insufficient scientific evidence to propose a specific biopsy scheme that could fit every candidate, providing accurate characterization of the disease in the individual patient. Further research is necessary to establish solid selection protocols that would reliably identify appropriate candidates for FT of PCa.
Collapse
Affiliation(s)
- Matvey Tsivian
- Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
| | | | | | | | | |
Collapse
|
65
|
Abstract
OBJECTIVE In patients with clinically suspected local recurrence of prostate cancer, a lobulated hyperintense mass in the radical prostatectomy fossa can be readily visualized with T2-weighted MRI, but this imaging technique is less successful after treatments such as radiation therapy, high-intensity focused ultrasound, and cryosurgery. We describe the additional value of functional techniques in the assessment of local recurrence. CONCLUSION The use of functional MRI techniques such as MR spectroscopy, diffusion-weighted imaging, and dynamic contrast-enhanced MRI has shown promise in increasing overall imaging performance in the detection of local recurrence.
Collapse
|
66
|
Engelbrecht MR, Puech P, Colin P, Akin O, Lemaître L, Villers A. Multimodality Magnetic Resonance Imaging of Prostate Cancer. J Endourol 2010; 24:677-84. [DOI: 10.1089/end.2009.0597] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Affiliation(s)
- Marc R. Engelbrecht
- Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Philippe Puech
- Université Lille Nord de France, Lille, France
- CHU Lille, Radiology Department, Lille, France
- INSERM, U703, Loos, France
| | - Pierre Colin
- Université Lille Nord de France, Lille, France
- INSERM, U703, Loos, France
- CHU Lille, Urology Deparment, Lille, France
| | - Oguz Akin
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Laurent Lemaître
- Université Lille Nord de France, Lille, France
- CHU Lille, Radiology Department, Lille, France
| | | |
Collapse
|
67
|
Lecornet E, Ahmed HU, Moore CM, Emberton M. Conceptual Basis for Focal Therapy in Prostate Cancer. J Endourol 2010; 24:811-8. [DOI: 10.1089/end.2009.0654] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Emilie Lecornet
- Division of Surgery and Interventional Sciences, University College of London, London, United Kingdom
- Service d'Urologie, Hôpital Claude Huriez, Lille, France
| | - Hashim Uddin Ahmed
- Division of Surgery and Interventional Sciences, University College of London, London, United Kingdom
| | - Caroline M. Moore
- Division of Surgery and Interventional Sciences, University College of London, London, United Kingdom
| | - Mark Emberton
- Division of Surgery and Interventional Sciences, University College of London, London, United Kingdom
- UCLH/UCL Comprehensive Biomedical Research Centre, London, United Kingdom
| |
Collapse
|
68
|
Abstract
Successful and accurate imaging of prostate cancer is integral to its clinical management from detection and staging to subsequent monitoring. Various modalities are used including ultrasound, computed tomography, and magnetic resonance imaging, with the greatest advances seen in the field of magnetic resonance.
Collapse
Affiliation(s)
- Jalil Afnan
- Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
| | | |
Collapse
|
69
|
Liu T, Mansukhani MM, Benson MC, Ennis R, Yoshida E, Schiff PB, Zhang P, Zhou J, Kutcher GJ. A feasibility study of novel ultrasonic tissue characterization for prostate-cancer diagnosis: 2D spectrum analysis of in vivo data with histology as gold standard. Med Phys 2009; 36:3504-11. [PMID: 19746784 DOI: 10.1118/1.3166360] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
This study demonstrates the feasibility of using a novel 2D spectrum ultrasonic tissue characterization (UTC) technique for prostate-cancer diagnosis. Normalized 2D spectra are computed by performing Fourier transforms along the range (beam) and the cross-range directions of the digital radio-frequency echo data, then dividing by a reference spectrum. This 2D spectrum method provides axial and lateral information of tissue microstructures, an improvement over the current 1D spectrum analysis which only provides axial information. A pilot study was conducted on four prostate-cancer patients who underwent radical prostatectomies. Cancerous and noncancerous regions of interest, identified through histology, were compared using four 2D spectral parameters: peak value and 3 dB width of the radially integrated spectral power (RISP), slope and intercept of the angularly integrated spectral power (AISP). For noncancerous and cancerous prostatic tissues, respectively, our investigation yielded 23 +/- 1 and 26 +/- 1 dB for peak value of RISP, 7.8 +/- 0.5 degrees and 7.6 +/- 0.6 degrees for 3 dB of RISP, -2.1 +/- 0.2 and -2.7 +/- 0.4 dB/MHz for slope of AISP, and 92 +/- 5 and 112 +/- 6 dB for intercept of AISP. Preliminary results indicated that 2D spectral UTC has the potential for identifying tumor-bearing regions within the prostate gland.
Collapse
Affiliation(s)
- Tian Liu
- Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
70
|
Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer. Top Magn Reson Imaging 2009; 19:261-72. [PMID: 19512848 DOI: 10.1097/rmr.0b013e3181aa6b50] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Prostate cancer is a major health problem, and the exploration of noninvasive imaging methods that have the potential to improve specificity while maintaining high sensitivity is still critically needed. Tissue changes induced by tumor growth can be visualized by magnetic resonance imaging (MRI) methods. Current MRI methods include conventional T2-weighted imaging, diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping and magnetic resonance spectroscopy (MRS). Techniques such as DWI/ADC provide functional information about the behavior of water molecules in tissue; MRS can provide biochemical information about the presence or absence of certain metabolites, such as choline, creatine, and citrate. Finally, vascular parameters can be investigated using dynamic contrast-enhanced MRI. Moreover, with whole-body MRI and DWI, metastatic disease can be evaluated in 1 session and may provide a way to monitor treatment. Therefore, when combining these various methods, a multiparametric data set can be built to assist in the detection, localization, assessment of prostate cancer aggressiveness, and tumor staging. Such a comprehensive approach offers more power to evaluate prostate disease than any single measure alone. In this article, we focus on the role of DWI/ADC and MRS in the detection and characterization using both in vivo and ex vivo imaging of prostate pathology.
Collapse
|
71
|
|
72
|
Editorial Comment on: Combined Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Imaging in the Diagnosis of Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2009; 55:591. [DOI: 10.1016/j.eururo.2008.10.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
73
|
Bosio A, Destefanis P, De Maria C, Bisconti A, Carchedi M, Negro C, Buffardi A, Petracchini M, Munoz F, Cirillo S, Fontana D. Re-Biopsies of the Prostate after Endo-Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) in Patients with ASAP: Preliminary Results. Urologia 2009. [DOI: 10.1177/039156030907604s02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Introduction e Objectives There are some evidences that the combination of EndoMRI and MRS might be able to limit the number of iterative biopsies in patients with negative biopsies of the prostate and a still rising PSA. The aim of this study is to evaluate the possible role of EndoMRI/MRS in patients with ASAP. Methods From November 2005 to September 2008 we enrolled 28 consecutive patients diagnosed with ASAP at a TRUS-guided needle prostate biopsy. All patients underwent prostatic EndoMRI and MRS. A prostatic zone was classified as: suspicious for prostate cancer if low intensity signal was present on T2-weighted images and/or if the choline + creatine / citrate ratio was >0.86; equivocal or negative otherwise. A subsequent 12-core needle prostate biopsy was performed and supplementary biopsies were added in the suspicious zones. The results of MRI/MRS were then compared with histological findings. Results The combination of EndoMRI and MRS was suspicious for cancer in 70% of patients, equivocal in 23% and negative in 7%. Histological findings at re-biopsy included: prostate cancer in 35%, ASAP in 23%, BPH or prostatitis in 42%. In 78% of patients diagnosed with prostate cancer the combination MRI/MRS was suspicious and in 22% equivocal. In all patients the cancer was found in suspicious zones at MRI/MRS where targeted biopsies were performed. Conclusions The combination of EndoMRI and MRS proved to have a good sensitivity but a poor specificity in identifying a concurrent prostate cancer among patients with ASAP. The location of positive cores for prostate cancer was consistent with the suspicious zones at MRI/MRS.
Collapse
Affiliation(s)
- A. Bosio
- Divisione Universitaria di Urologia 2, Ospedale “San Giovanni Battista, Molinette”, Torino
| | - P. Destefanis
- Divisione Universitaria di Urologia 2, Ospedale “San Giovanni Battista, Molinette”, Torino
| | - C. De Maria
- Divisione Universitaria di Urologia 2, Ospedale “San Giovanni Battista, Molinette”, Torino
| | - A. Bisconti
- Divisione Universitaria di Urologia 2, Ospedale “San Giovanni Battista, Molinette”, Torino
| | - M. Carchedi
- Divisione Universitaria di Urologia 2, Ospedale “San Giovanni Battista, Molinette”, Torino
| | - C. Negro
- Divisione Universitaria di Urologia 2, Ospedale “San Giovanni Battista, Molinette”, Torino
| | - A. Buffardi
- Divisione Universitaria di Urologia 2, Ospedale “San Giovanni Battista, Molinette”, Torino
| | - M. Petracchini
- Servizio di Radiodiagnostica, Istituto per la Ricerca e la Cura del Cancro di Candiolo (Torino)
| | - F. Munoz
- Divisione Universitaria di Radioterapia, Ospedale “San Giovanni Battista, Molinette”, Torino
| | - S. Cirillo
- Servizio di Radiodiagnostica, Istituto per la Ricerca e la Cura del Cancro di Candiolo (Torino)
| | - D. Fontana
- Divisione Universitaria di Urologia 2, Ospedale “San Giovanni Battista, Molinette”, Torino
| |
Collapse
|